Jarl Ulf Birger Jungnelius
Director/Board Member chez ONCOPEPTIDES AB
Fortune : 35 106 $ au 31/03/2024
Profil
Jarl Ulf Birger Jungnelius is currently an Independent Director at Oncopeptides AB, a Director at CarpoNovum AB, a Director at Beactica Therapeutics AB, an Independent Director at Biovica International AB, a Director at Mesothelioma Applied Research Foundation, Inc., a Director at Monocl AB, the Chief Medical Officer at NOXXON Pharma AG, and the Managing Partner at Healthcom GmbH.
He previously served as the Chairman at Isofol Medical AB, the VP-Clinical Research & Development, Solid Tumors at Celgene Corp., the Principal at Eli Lilly & Co., the Vice President-Oncology Clinical Development at Takeda Corp., and the Full Development Leader at Pfizer NV.
He was also a Member-Supervisory Board at Ryvu Therapeutics SA and an Advisor-Senior Medical at TME Pharma NV.
He holds a doctorate degree from Karolinska Institutet.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ONCOPEPTIDES AB
0,06% | 31/12/2022 | 57 750 ( 0,06% ) | 35 106 $ | 31/03/2024 |
Postes actifs de Jarl Ulf Birger Jungnelius
| Sociétés | Poste | Début |
|---|---|---|
| ONCOPEPTIDES AB | Director/Board Member | 01/04/2011 |
| BIOVICA INTERNATIONAL AB | Director/Board Member | 01/01/2014 |
| Mesothelioma Applied Research Foundation, Inc. | Director/Board Member | - |
Monocl AB
 Monocl AB Internet Software/ServicesTechnology Services Monocl AB develops cloud-based stakeholder platform. Its areas include business development, valuation, and communication. The company was founded by Björn Carlsson and Tobias Thornblad in 2011 and is headquartered in Gothenburg, Sweden. | Director/Board Member | 01/03/2013 |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Chief Tech/Sci/R&D Officer | 01/02/2017 |
| Healthcom GmbH | Corporate Officer/Principal | 01/05/2014 |
Beactica Therapeutics AB
 Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Director/Board Member | 19/06/2023 |
CarpoNovum AB
 CarpoNovum AB Medical SpecialtiesHealth Technology CarpoNovum AB develops and provides surgical instruments. Its products include CARP RapAn, CARP FixAid, CARP FixAid no cath, CARP LapAid, CARP DMHC, CARP pressure measure device and CARP test devices. The company was founded by Henrik Tobias Thorlacius and Grönberg Anders Georg in 2006 and is headquartered in Halmstad, Sweden. | Director/Board Member | - |
Anciens postes connus de Jarl Ulf Birger Jungnelius
| Sociétés | Poste | Fin |
|---|---|---|
| ISOFOL MEDICAL AB | Chief Executive Officer | 28/02/2023 |
| ░░░ ░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░ ░░░░░ ░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Jarl Ulf Birger Jungnelius
| Karolinska Institutet | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| BIOVICA INTERNATIONAL AB | Health Technology |
| ISOFOL MEDICAL AB | Health Technology |
| RYVU THERAPEUTICS S.A. | Health Technology |
| TME PHARMA N.V. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Takeda Corp.
 Takeda Corp. Pharmaceuticals: MajorHealth Technology Takeda Corp. manufactures and distributes pharmaceutical products. The company is headquartered in Tokyo, Japan | Health Technology |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
CarpoNovum AB
CarpoNovum AB Medical SpecialtiesHealth Technology CarpoNovum AB develops and provides surgical instruments. Its products include CARP RapAn, CARP FixAid, CARP FixAid no cath, CARP LapAid, CARP DMHC, CARP pressure measure device and CARP test devices. The company was founded by Henrik Tobias Thorlacius and Grönberg Anders Georg in 2006 and is headquartered in Halmstad, Sweden. | Health Technology |
Beactica Therapeutics AB
Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Distribution Services |
| Pfizer NV/SA | |
| Mesothelioma Applied Research Foundation, Inc. | |
Monocl AB
Monocl AB Internet Software/ServicesTechnology Services Monocl AB develops cloud-based stakeholder platform. Its areas include business development, valuation, and communication. The company was founded by Björn Carlsson and Tobias Thornblad in 2011 and is headquartered in Gothenburg, Sweden. | Technology Services |
| Healthcom GmbH |
